This study investigates pancreatic cancer in Ashkenazi Jewish patients. It focuses on the frequency of specific genetic mutations, namely BRCA1 and BRCA2, which are often found in these patients.
The study evaluates the presence of these genetic mutations without detailing specific procedures or participant assignments. It looks at factors such as disease-free survival and stages of the disease.
- Who can participate: Individuals diagnosed with pancreatic cancer who are of Ashkenazi Jewish descent and are part of the Columbia Pancreatic Cancer Prevention Program Registry are eligible. Participants must be 18 years or older and able to provide informed consent.
- Study details: Participants will undergo genetic testing to identify BRCA1 and BRCA2 mutations. This involves testing for specific mutations to understand their frequency in the studied population.
How understandable was the trial content above?
Hard to understand
Easy to understand